Investment
Features
FeesSafety
Academy
More
Pluang+

WisdomTree US High Dividend ETF upgraded to buy after price drop and attractive valuation

Analyst Insights
28 Sep 2026
Seeking Alpha
View Source
Bullish
WisdomTree US High Dividend ETF upgraded to buy after price drop and attractive valuation

The WisdomTree US High Dividend ETF (DHS) has been upgraded to a buy rating following its recent price pullback and improved valuation metrics. DHS now trades at a price-to-earnings ratio of 13.8 with a long-term EPS growth rate of 9.15%, resulting in a PEG ratio below 1.5, indicating potential undervaluation. Although technical signals are mixed, the ETF is nearing its rising 200-day moving average and shows oversold momentum, suggesting a favorable risk/reward profile. Despite recent pressure from rising Treasury yields, a cooling rate environment and seasonal trends could support a bullish fourth quarter for DHS.

The WisdomTree US High Dividend ETF (DHS) is discussed in this story. For readers following US stocks, here is Pluang's market snapshot as of Sep 29, 2026 03:12 WIB: out of 150 priced US stocks tradable on Pluang, 55 rose and 93 fell today. Notable movers include INTC at USD 115.86 with a 1-day change of -5.80%, AFRM at USD 67.39 down 5.77%, and OPEN at USD 2.44 down 5.06% with 100% buy order activity.

More News

Several high-volume stocks plunge sharply amid profit-taking despite positive updates.

Several high-volume stocks plunge sharply amid profit-taking despite positive updates.

Several high-volume stocks including ITG Inc, Adicet Bio, Jaguar Health, Ocular Therapeutix, and Greenland Mines experienced sharp declines despite recent positive company news. The drops, ranging from about 19% to over 32%, appear driven by profit-t...

Market News
Bearish
2 hours ago
Stocks jump on clinical trial updates, acquisition deals, and trading momentum.

Stocks jump on clinical trial updates, acquisition deals, and trading momentum.

Kodiak Sciences surged 178% following positive Phase III trial updates for a wet age-related macular degeneration treatment. Lifecore Biomedical rose 55% after agreeing to a $663.7 million acquisition by Webster Equity Partners. YD Bio gained 22%, li...

Market News
Bullish
2 hours ago
Lifecore Biomedical shares jump 55% on acquisition news, analyst downgrades to Hold.

Lifecore Biomedical shares jump 55% on acquisition news, analyst downgrades to Hold.

Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 m...

Market News
Bullish
3 hours ago
Espey director sells shares amid stock valued 112% above fair value despite strong earnings.

Espey director sells shares amid stock valued 112% above fair value despite strong earnings.

A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 mi...

Market News
Neutral
3 hours ago
Vail Resorts beats Q4 revenue estimates, targets $106M in cost savings for profit boost

Vail Resorts beats Q4 revenue estimates, targets $106M in cost savings for profit boost

Vail Resorts reported Q4 earnings per share of -$5.34, slightly better than expected, with revenue of $278.1 million surpassing estimates. The company benefited from a 5.2% rise in mountain revenues, driven by strong pass sales in Australia and stabl...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App